nChroma Bio Receives Authorization of Clinical Trial Application to Initiate First-in-Human Study for Epigenetic Silencer CRMA-1001 for the Treatment of Chronic Hepatitis B

First CTA authorization marks nChroma's transition to a clinical-stage company; first patient dosing in Phase 1/2 trial planned for early 2026 Preclinical studies demonstrated CRMA-1001 delivers ...
Business Wire

Precision BioSciences Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies ...
Business Wire

Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, ...
Medscape

Molecular Methods in the Diagnosis and Management of Chronic Hepatitis B

The sensitivities of the aforementioned assays vary a lot. Direct sequencing-based assays have limited sensitivity, while assays based on PCR restriction fragment-length polymorphisms (RFLPs), ...
Nasdaq

Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium

Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other ...
MedPage Today

RNA Interference Therapeutic Shows Promise for Chronic Hepatitis B

In adults with chronic hepatitis B infection receiving viral suppression therapy, coupling an investigational small interfering RNA therapy with an immunomodulator led to substantial declines in blood ...
Nasdaq

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B

DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...
Seeking Alpha

Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis ...

DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for ...
JSTOR Daily

N6-methyladenosine modification of the 5′ epsilon structure of the HBV pregenome RNA regulates its encapsidation by the viral core protein

Hepatitis B virus (HBV) contains a partially double-stranded DNA genome. During infection, its replication is mediated by reverse transcription (RT) of an RNA intermediate termed pregenomic RNA (pgRNA ...
Labroots

New Insights Into Hepatitis B Infection Reveal a Potential Treatment

Hepatitis B virus (HBV) causes hepatitis B. Worldwide, hepatitis B is thought to be the second deadliest infection; it's estimated that about five percent of the global population have the disease.